GLAXOSMITHKLINE PLC Form 6-K March 25, 2013

FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending March 2013

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

\_

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Notification of	Transactions	of Dimostone	Dancono	Dischanging	- Mama	aamial Daa	aanaihility	· on Comma	atad Damaana
Nounication of	Transactions	or Directors.	Persons	Discharging	2 Ivranas	geriai Kesi	DOUSIDHILV	or Conne	cted Persons
		,			,	5			

I give below details of a change in the interests of a Person Discharging Managerial Responsibility in American Depositary Shares (ADSs) of GlaxoSmithKline plc on 22 March 2013:

Mr W C Louv per ADS.

The sale of 16,000 ADSs in GlaxoSmithKline plc at a price of \$46.44

The Company and the above mentioned individual were advised of this transaction on 22 March 2013.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte Company Secretary

25 March 2013

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: March 25, 2013

By: VICTORIA WHYTE

-----

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc